RETRANSMISSION: Goldman Small Cap Research Publishes New Research Report on Sigyn Therapeutics Inc.
Sigyn Therapeutics (OTCQB:SIGY) has been featured in a new research report by Goldman Small Cap Research, highlighting the company's development of next-generation blood purification therapies. The company's flagship product, Sigyn Therapy™, is a first-in-class device targeting severe inflammatory disorders, primarily sepsis and end stage renal disease (ESRD).
The device has demonstrated capability to reduce bacterial toxins, inflammatory cytokines, hepatic toxins, and infectious viral pathogens from human blood plasma. Additionally, Sigyn is developing medical devices to enhance cancer drug treatment effectiveness.
According to the research report, Sigyn plans to submit multiple Breakthrough Device submissions this year and expects to commence an ESRD feasibility study within the next 12 months. The study could yield data within 6 months of completion. Goldman Small Cap Research has issued a price target for SIGY, suggesting the company is currently undervalued compared to peers.
Sigyn Therapeutics (OTCQB:SIGY) è stata oggetto di un nuovo rapporto di ricerca da parte di Goldman Small Cap Research, che mette in luce lo sviluppo da parte dell'azienda di terapie di purificazione del sangue di nuova generazione. Il prodotto di punta dell'azienda, Sigyn Therapy™, è un dispositivo innovativo che si rivolge a gravi disturbi infiammatori, in particolare sepsi e insufficienza renale terminale (ESRD).
Il dispositivo ha dimostrato la capacità di ridurre tossine batteriche, citochine infiammatorie, tossine epatiche e agenti patogeni virali infettivi dal plasma sanguigno umano. Inoltre, Sigyn sta sviluppando dispositivi medici per migliorare l'efficacia dei trattamenti farmacologici contro il cancro.
Secondo il rapporto di ricerca, Sigyn prevede di presentare quest'anno più richieste per dispositivi innovativi (Breakthrough Device) e si aspetta di avviare uno studio di fattibilità sull'ESRD entro i prossimi 12 mesi. Lo studio potrebbe fornire dati entro 6 mesi dal completamento. Goldman Small Cap Research ha fissato un prezzo obiettivo per SIGY, suggerendo che l'azienda è attualmente sottovalutata rispetto ai concorrenti.
Sigyn Therapeutics (OTCQB:SIGY) ha sido destacada en un nuevo informe de investigación de Goldman Small Cap Research, que resalta el desarrollo por parte de la compañía de terapias de purificación sanguínea de próxima generación. El producto principal de la empresa, Sigyn Therapy™, es un dispositivo pionero que se enfoca en trastornos inflamatorios severos, principalmente sepsis y enfermedad renal terminal (ESRD).
El dispositivo ha demostrado la capacidad de reducir toxinas bacterianas, citoquinas inflamatorias, toxinas hepáticas y patógenos virales infecciosos del plasma sanguíneo humano. Además, Sigyn está desarrollando dispositivos médicos para mejorar la efectividad del tratamiento farmacológico contra el cáncer.
Según el informe de investigación, Sigyn planea presentar múltiples solicitudes de Dispositivo Innovador (Breakthrough Device) este año y espera comenzar un estudio de viabilidad para ESRD en los próximos 12 meses. El estudio podría proporcionar datos dentro de los 6 meses posteriores a su finalización. Goldman Small Cap Research ha establecido un precio objetivo para SIGY, sugiriendo que la compañía está actualmente subvalorada en comparación con sus pares.
Sigyn Therapeutics (OTCQB:SIGY)는 Goldman Small Cap Research의 새로운 연구 보고서에 소개되어, 차세대 혈액 정화 치료법 개발을 강조했습니다. 회사의 대표 제품인 Sigyn Therapy™는 중증 염증 질환, 주로 패혈증 및 말기 신장 질환(ESRD)을 대상으로 하는 혁신적인 장치입니다.
이 장치는 인간 혈장 내의 박테리아 독소, 염증성 사이토카인, 간 독소 및 감염성 바이러스 병원체를 감소시키는 능력을 입증했습니다. 또한 Sigyn은 암 치료제의 효능을 향상시키기 위한 의료기기도 개발 중입니다.
연구 보고서에 따르면, Sigyn은 올해 다수의 혁신 의료기기(Breakthrough Device) 제출을 계획하고 있으며, 향후 12개월 내에 ESRD에 대한 타당성 연구를 시작할 예정입니다. 이 연구는 완료 후 6개월 내에 데이터를 제공할 수 있습니다. Goldman Small Cap Research는 SIGY에 대한 목표 주가를 제시하며, 현재 동종 기업 대비 저평가되어 있다고 평가했습니다.
Sigyn Therapeutics (OTCQB:SIGY) a été mis en avant dans un nouveau rapport de recherche de Goldman Small Cap Research, soulignant le développement par l'entreprise de thérapies de purification sanguine de nouvelle génération. Le produit phare de la société, Sigyn Therapy™, est un dispositif innovant ciblant les troubles inflammatoires sévères, principalement la sepsie et l'insuffisance rénale terminale (ESRD).
Le dispositif a démontré sa capacité à réduire les toxines bactériennes, les cytokines inflammatoires, les toxines hépatiques et les agents pathogènes viraux infectieux dans le plasma sanguin humain. De plus, Sigyn développe des dispositifs médicaux pour améliorer l'efficacité des traitements médicamenteux contre le cancer.
Selon le rapport de recherche, Sigyn prévoit de soumettre plusieurs dossiers de dispositifs révolutionnaires (Breakthrough Device) cette année et s'attend à commencer une étude de faisabilité sur l'ESRD dans les 12 prochains mois. L'étude pourrait fournir des données dans les 6 mois suivant son achèvement. Goldman Small Cap Research a fixé un objectif de cours pour SIGY, suggérant que la société est actuellement sous-évaluée par rapport à ses pairs.
Sigyn Therapeutics (OTCQB:SIGY) wurde in einem neuen Forschungsbericht von Goldman Small Cap Research vorgestellt, der die Entwicklung von Therapien zur Blutreinigung der nächsten Generation durch das Unternehmen hervorhebt. Das Flaggschiff-Produkt des Unternehmens, Sigyn Therapy™, ist ein neuartiges Gerät, das auf schwere entzündliche Erkrankungen abzielt, insbesondere Sepsis und Endstadium der Nierenerkrankung (ESRD).
Das Gerät hat gezeigt, dass es in der Lage ist, bakterielle Toxine, entzündliche Zytokine, Lebertoxine und infektiöse virale Krankheitserreger aus menschlichem Blutplasma zu reduzieren. Darüber hinaus entwickelt Sigyn medizinische Geräte, um die Wirksamkeit von Krebsmedikamenten zu verbessern.
Dem Forschungsbericht zufolge plant Sigyn, in diesem Jahr mehrere Anträge für Breakthrough Devices einzureichen und erwartet, innerhalb der nächsten 12 Monate eine Machbarkeitsstudie für ESRD zu starten. Die Studie könnte innerhalb von 6 Monaten nach Abschluss Daten liefern. Goldman Small Cap Research hat ein Kursziel für SIGY ausgegeben und deutet darauf hin, dass das Unternehmen derzeit im Vergleich zu Wettbewerbern unterbewertet ist.
- None.
- No FDA-approved treatments yet
- Currently trading on OTCQB market rather than major exchange
- Feasibility study results won't be available for at least 18 months
Underfollowed Innovator to Enjoy Profile Raise
BALTIMORE, MD / ACCESS Newswire / July 1, 2025 / Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sectors, announced today that it has published a new research report on Sigyn Therapeutics Inc. (OTCQB:SIGY), a developer of next-generation blood purification therapies to address life-threatening conditions that carry no FDA-approved treatments. The Goldman report carries a price target. To view the new research report, along with disclosures and disclaimers, or to download the report in its entirety, please visit: https://goldmansmallcapresearch.com/opportunity-research/powerful-dual-track/.
Sigyn Therapeutics, Inc. is developing next-generation blood purification therapies to address life-threatening conditions with no FDA-approved treatments. Sigyn Therapy™ is a first-in-class device to address severe inflammatory disorders. Its primary targeted conditions are sepsis and end stage renal disease. The flagship platform therapy has been demonstrated to reduce the presence of bacterial toxins (including endotoxin), inflammatory cytokines, hepatic toxins, and infectious viral pathogens from human blood plasma. The Company is also developing medical devices to optimize the benefit of drugs to treat cancer.
In the Opportunity Research report, analyst Rob Goldman reviews this undervalued and underfollowed innovator including upcoming milestones and events, clinical achievements, unique opportunities in multi-billion-dollar indications, and a price target for SIGY.
SIGY: Game Changing Approach
Goldman commented, "Sigyn is poised to change the way acute, life-threatening inflammatory conditions induced by endotoxemia and other concurrent inflammation. Many of these conditions have no approved therapy and represent billions in market size. The primary targeted conditions include end stage renal disease and sepsis, the #1 cause of deaths in hospitals worldwide. The Company also has a deep oncology portfolio."
Potential Near Term Valuation-Raising Milestones Ahead
"Sigyn has reported favorable in vitro results and is poised to submit multiple Breakthrough Device submissions this year. The Company could be awarded these designations in the coming quarter," noted Goldman. "A planned ESRD feasibility study should commence in the next 12 months. Data could be derived from this trial within 6 months following the end of the study."
Upcoming Events Could Raise Profile
"Our six-month price target reflects both the current undervalued and underfollowed status of Sigyn versus peers, but also the value of future milestones. In our view, Sigyn's primary platform offers valuable, hidden features which could serve as a valuation driver. Looking ahead, future milestones could eventually lead to an M&A event," concluded Goldman.
About Goldman Small Cap Research: Founded in 2009by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces sponsored and non-sponsored small cap and microcap stock research reports, articles, stock market blogs, and popular investment newsletters.
Goldman Small Cap Research is not in any way affiliated with Goldman Sachs & Co.
This press release contains excerpts of our most recently published company report on Sigyn Therapeutics Inc. ("The Company"). The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. Goldman Small Cap Research relied solely upon information derived from Sigyn Therapeutics Inc. The information includes authorized press releases or legal disclosures made in their filings with the U.S. Securities and Exchange Commission http://www.sec.gov.
Separate from the factual content of our update about the Company, we may from time to time include our own opinions about the Company, its business, markets, and opportunities. Any opinions we may offer about the Company are solely our own, and are made in reliance upon our rights under the First Amendment to the U.S. Constitution, and are provided solely for the general opinionated discussion of our readers. Our opinions should not be considered to be complete, precise, accurate, or current investment advice. Statements herein may contain forward-looking statements and are subject to significant risks and uncertainties affecting results.
A Goldman Small Cap Research report, update, newsletter, article, trading alert, corporate profile, sector or industry snapshot, podcast interview, or press release is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed and is to be used for informational purposes only. Please read all associated full disclosures, disclaimers, and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other regulatory agency. To download this research report, visit www.goldmansmallcapresearch.com. Goldman Small Cap Research did not receive any compensation for this report. In 2021, Goldman Small Cap Research was compensated by the Company in the amount of
Goldman Small Cap Research
Rob Goldman, Analyst
410-800.7980
rob@goldmansmallcapresearch.com
SOURCE: Goldman Small Cap Research
View the original press release on ACCESS Newswire
FAQ
What is Sigyn Therapeutics' (SIGY) main product?
What conditions does Sigyn Therapeutics (SIGY) target with its blood purification therapy?
What are the upcoming milestones for Sigyn Therapeutics (SIGY)?
What has Sigyn Therapy demonstrated in testing so far?
When will Sigyn Therapeutics (SIGY) begin its ESRD feasibility study?
